← Back to Search

Patient-Reported Data Tracking for Cancer

N/A

Recruiting

Led By Katie Reeder-Hayes

Research Sponsored by UNC Lineberger Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have not yet initiated cancer treatment on the date of enrollment

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 180 days post-enrollment

Awards & highlights

Study Summary

This trial aims to identify cancer patients at risk of delayed treatment, so interventions can be provided to get them treatment faster. 240 colorectal and breast cancer patients will be studied.

Who is the study for?

This trial is for adults over 18 with a recent diagnosis of breast or colorectal cancer who plan to receive treatment at the University of North Carolina. They must be able to get and respond to surveys electronically and give consent. Those without email or smartphone access, unable to consent, or not fluent in English cannot join.Check my eligibility

What is being tested?

The study tests an electronic tool where patients report issues that might delay their cancer treatment. It aims to identify if there's a link between race, social factors, and treatment delays using patient feedback and health records.See study design

What are the potential side effects?

Since this trial involves completing weekly surveys rather than testing medications, there are no direct medical side effects associated with participating in this research.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have not started any cancer treatment yet.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 180 days post-enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 180 days post-enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 180 days post-enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Electronic patient-reported outcome (ePRO) confirming treatment initiation

Feasibility of Electronic patient-reported outcome (ePRO)

Secondary outcome measures

Delayed Treatment

Proportion of treatment delay

Time to ePRO-reported treatment

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: electronic patient-reported outcome (ePRO) questionnaires.Experimental Treatment1 Intervention

Subjects with colon or breast carcinoma will respond to weekly electronic patient-reported outcome (ePRO) questionnaires.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor

351 Previous Clinical Trials

88,093 Total Patients Enrolled

51 Trials studying Breast Cancer

27,746 Patients Enrolled for Breast Cancer

Katie Reeder-HayesPrincipal InvestigatorUNC Lineberger Comprehensive Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still an opportunity to join this medical study?

"Evidenced by the information available on clinicaltrials.gov, this trial is no longer accepting participants. This experiment was first posted on December 1st 2023 and had its last update recorded in October 17th 2023. Despite that fact, there are still 3082 active trials searching for volunteers at this time."

Answered by AI

What are the key aims of this medical experiment?

"This clinical trial's primary outcome will be measured over a Baseline to 56 days post-enrollment period, focusing on Electronic patient-reported outcomes (ePRO) indicating treatment initiation. Secondary objectives involve calculating the Time to ePRO-reported treatment - from initial diagnosis until when the patient reports beginning therapy in an assigned survey - and Proportion of Treatment Delay - amounting to any time between first documentation of malignancy and initial therapeutic intervention that exceeds 56 days. Lastly, Time To Treatment In Days assesses how long it took from initial detection of cancer until commencement of treatments is calculated."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment

2023. "The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06096623.

All > Colorectal Cancer Raleigh